Status:
COMPLETED
ADVANCE: An Observational Study To Determine Bortezomib Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies.
Lead Sponsor:
Janssen-Cilag B.V.
Conditions:
Multiple Myeloma
Hematological Neoplasms
Eligibility:
All Genders
18+ years
Brief Summary
The primary aim of this observational study is to collect safety and effectiveness data for bortezomib used at first relapse in a group of multiple myeloma patients who received specific and well defi...
Detailed Description
There is a need by physicians to evaluate the results of bortezomib treatment in a homogenous patient population with regard to the multiple myeloma treatments in first line. For that reason the curre...
Eligibility Criteria
Inclusion
- Patients have to sign a statement that they agree with collection of their clinical data for this project
- patients had a first relapse or progressive disease after treatment in the HOVON-49 or HOVON-50 study and will be treated with bortezomib.
Exclusion
- Prior enrollment in HOVON-54 study
Key Trial Info
Start Date :
September 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2011
Estimated Enrollment :
11 Patients enrolled
Trial Details
Trial ID
NCT00440479
Start Date
September 1 2006
End Date
January 1 2011
Last Update
April 16 2015
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Bergen op Zoom, Netherlands
2
Breda, Netherlands
3
Ede Gld, Netherlands
4
Flushing, Netherlands